The three human RAS proteins are mutated and constitutively activated in ∼20% of cancers leading to cell growth and proliferation. For the past three decades, many attempts have been made to inhibit these proteins with little success. Recently; however, multiple methods have emerged to inhibit KRAS, the most prevalently mutated isoform. These methods and the underlying biology will be discussed in this review with a special focus on KRAS-plasma membrane interactions.

中文翻译：

---

癌细胞中的 RAS 功能：将膜生物学和生物化学转化为新的治疗方法。

这三种人类 RAS 蛋白在约 20% 的癌症中发生突变和组成型激活，导致细胞生长和增殖。在过去的 30 年中，已经进行了许多尝试来抑制这些蛋白质，但收效甚微。最近; 然而，已经出现了多种方法来抑制 KRAS，这是最普遍的突变亚型。本综述将讨论这些方法和基础生物学，特别关注 KRAS-质膜相互作用。